Novotech earns best CRO recognition at 2025 Asia-Pacific Awards

AUSTRALIA – Novotech, a leading contract research organization (CRO) dedicated to providing biotech and small- to mid-size pharmaceutical companies with an accelerated path to market, has been named the Best CRO in Australia at the Asia-Pacific Biopharma Excellence Awards (ABEA) 2025.

The ABEA celebrates excellence in clinical trials and honors organizations, experts, and technologies that drive innovation.

According to a press release, voting is conducted entirely within the industry, ensuring that winners are recognized by their peers.

Chris Chong, Novotech’s Senior Director of Clinical Services, accepted the award at a ceremony held in Singapore.

“We thank the Asia Pacific Biopharma Excellence Awards for this recognition,” Chong said.

“This award reflects the dedication of our teams worldwide who support biopharma innovation. Our clients and partners entrust us with their research, and we take pride in accelerating the development of new therapies.

“Novotech remains committed to advancing clinical research, strengthening partnerships, and maintaining high standards in biopharma development.”

With over 30 offices worldwide and partnerships with more than 5000 trial sites, Novotech continues to build its reputation as a top-tier CRO.

The company has also been recognized by Frost & Sullivan’s CRO Company of the Year award for 19 consecutive years, showcasing its consistency and dedication to excellence. The recognition comes amid a wave of notable developments in Australia’s biotech landscape.

In January 2025, Genetic Cures for Kids, a nonprofit organization, partnered with PackGene Biotech and the Belfer Gene Therapy Core Facility at Weill Cornell Medicine to develop gene therapy for hereditary spastic paraplegia type 56.

North Melbourne-based Telix Pharmaceuticals also secured an asset purchase agreement with ImaginAb, acquiring cutting-edge biologics technology.

Additionally, AdvanCell, a clinical-stage radiopharmaceutical company, completed an oversubscribed US $112 million Series C financing round.

Meanwhile, Cosette Pharmaceuticals announced plans to acquire all remaining shares of Mayne Pharma Group, establishing FDA-approved manufacturing sites in South Australia and North Carolina, U.S.